Let’s just say what we’re all thinking: 2020 was rough. It threw every element of our lives into disarray. We suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive and it was challenging, but it was also transformative. And while the past 12 months might have felt like 12 years, it’s time to look forward to what the future holds. If 2020 was the year of disruption, 2021 will be the year of mastering change.
In the nutraceutical industry, the more things change the more they stay the same. The industry went into 2020 with bright hopes about a regulatory pathway for cannabidiol (CBD) in supplements, an emphasis on sustainability, and the possibility of an update to the Dietary Supplement Health and Education Act (DSHEA). Since the U.S. Food and Drug Administration (FDA) was a little busy during 2020, the CBD and DSHEA questions are still on the table in 2021. And while sustainability remains important, nutraceutical companies had their hands full dealing with supply chain disruption from the pandemic.
In the full article linked below, SeerPharma's business partner MasterControl explores the following key topics:
New Suppliers and a Better Supply Chain
The pandemic wreaked havoc on supply chains in just about every industry. Travel restrictions and work from home orders kept companies from getting the components and ingredients they needed or greatly restricted the quantity they could get. This was certainly the case in nutraceuticals. Product packaging in particular proved to be a problem, especially those components that are also used in the pharmaceutical industry. When it came to ingredients, the biggest problem was with botanicals.
The Peril and Potential of the Pandemic
Every year the FDA finds supplement makers that have disease claims on their product labels or their websites. Typically, the agency focuses on those making the most blatant claims about the most serious diseases. Most of the nutraceutical industry tries to separate itself from these bad actors as much as possible by respecting the regulations surrounding claims and seeking to make the best quality product possible. However, it can be difficult for consumers to differentiate between these two types of companies.
The Industry Anticipates DSHEA 2.0
Perhaps 2.0 is misleading. Maybe 1.5 would be more accurate. What’s on the table isn’t a complete rewriting of the 1994 legislation.
Submit the form below to access the full MasterControl article The Past Is Prologue for Nutraceuticals: 3 Trends to Watch in 2021.
